Show simple item record

dc.contributor.authorBao, L
dc.contributor.authorAl-Assar, O
dc.contributor.authorDrynan, LF
dc.contributor.authorArends, MJ
dc.contributor.authorTyers, P
dc.contributor.authorBarker, RA
dc.contributor.authorRabbitts, TH
dc.date.accessioned2020-12-21T14:07:45Z
dc.date.issued2017-03-21
dc.identifier.citationScientific reports, 2017, 7 pp. 44899 - ?
dc.identifier.issn2045-2322
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4264
dc.identifier.eissn2045-2322
dc.identifier.doi10.1038/srep44899
dc.description.abstractHaemangioblastoma is a rare malignancy of the CNS where vascular proliferation causes lesions due to endothelial propagation. We found that conditionally expressing mutant Kras, using Rag1-Cre, gave rise to CNS haemangioblastoma in the cortex and cerebellum in mice that present with highly vascular tumours with stromal cells similar to human haemangioblastomas. The aberrant haemangioblastoma endothelial cells do not express mutant Kras but rather the mutant oncogene is expressed in CNS interstitial cells, including neuronal cells and progeny. This demonstrates a non-cell autonomous origin of this disease that is unexpectedly induced via Rag1-Cre expression in CNS interstitial cells. This is the first time that mutant RAS has been shown to stimulate non-cell autonomous proliferation in malignancy and suggests that mutant RAS can control endothelial cell proliferation in neo-vascularisation when expressed in certain cells.
dc.formatElectronic
dc.format.extent44899 - ?
dc.languageeng
dc.language.isoeng
dc.publisherNATURE PORTFOLIO
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectAnimals
dc.subjectMice, Transgenic
dc.subjectHumans
dc.subjectMice
dc.subjectHemangioblastoma
dc.subjectCerebellar Neoplasms
dc.subjectDisease Models, Animal
dc.subjectIncidence
dc.subjectGene Expression
dc.subjectMutation
dc.subjectGenes, Reporter
dc.subjectGenes, ras
dc.titleA non-cell autonomous mouse model of CNS haemangioblastoma mediated by mutant KRAS.
dc.typeJournal Article
dcterms.dateAccepted2017-02-14
rioxxterms.versionofrecord10.1038/srep44899
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-03-21
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfScientific reports
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics
pubs.publication-statusPublished
pubs.volume7
pubs.embargo.termsNot known
icr.researchteamChromosomal Translocations and Intracellular Antibody Therapeutics
dc.contributor.icrauthorRabbitts, Terence


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0